欧洲人类微生物组市场到 2025 年 - 按产品(益生菌、食品、益生元、医用食品、诊断设备、药物和补充剂)、疾病(肥胖、糖尿病、自身免疫性疾病、癌症、精神疾病等)进行区域分析和预测,应用(治疗和诊断)和国家

Historic Data: 2015-2016   |   Base Year: 2017   |   Forecast Period: 2018-2025


No. of Pages: 149    |    Report Code: TIPRE00003318    |    Category: Life Sciences

Europe Human Microbiome Market

欧洲人类微生物组市场预计将从 2017 年的 72.34 美元增至 2025 年的 3.4667 亿美元。预计 2018-2025 年该市场将以 22.2% 的复合年增长率增长。

< /span>

非传染性疾病 (NCDS) 的惊人增长、基于人类微生物组的疗法的开发力度加大以及基因组学的发展等因素推动了市场的增长和测序技术。然而,政府对先进疗法的严格监管和有限的了解可能会对未来几年市场的增长产生负面影响。

粪便微生物群移植(FMT)已发展成为抗生素治疗难治性艰难梭菌感染 (CDI) 的有效治疗方法。微生物群在胃肠道功能和人体生理学的其他方面发挥着重要作用,人们对研究 FMT 用于其他临床适应症的兴趣也越来越大。美国食品和药物管理局 (FDA) 将人类粪便归类为生物制剂,并确定其在粪便微生物移植 (FMT) 治疗和其他研究中的使用受到监管,以确保患者安全。使用 FMT 治疗复发性艰难梭菌感染 (RCDI) 不需要研究性新药 (IND) 许可证,但强烈鼓励并最终可能需要。

一些现有数据表明,利用粪便微生物群恢复肠道菌群可能是治疗难治性艰难梭菌感染的有效疗法。根据该研究,“粪便微生物群移植治疗复发性艰难梭菌感染患者” 2016 年发表在 Deutscher Ärzteverlag GmbH 上的结论是,FMT 是 rCDI 的一种安全有效的治疗选择,但 FMT 仅在德国的少数中心提供。因此,这种疗法的临床有效性为人类微生物组治疗在欧洲地区的发展提供了机会。

预计德国将在预测期内引领整个欧洲地区人类微生物组的采用。人类微生物组是该国的一个新兴领域,其发展正在国内广泛开展。德国进行的全基因组关联分析研究于 2016 年发表。该研究确定了维生素 D 受体的变异和影响肠道微生物群的其他宿主因素。

此外,德国在新技术和新工艺的创新和开发上投入了大量资金。例如,2017 年 4 月,德国科学委员会批准为图宾根微生物群和癌症研究所提供 5300 万欧元的资金。因此,考虑和分析上述因素,人类微生物组市场在未来很可能会以显着的速度增长。

展示:欧洲其他地区人类微生物组市场收入及预测至 2027 年(十亿美元)



欧洲人体微生物组-市场细分



按产品


•益生菌
•食品
•益生元
•药用食品
•诊断装置
•毒品
•补充剂

欧洲人体微生物组-市场细分



按疾病< /strong>
•肥胖
•糖尿病
•自身免疫性疾病
•癌症
•精神障碍
•其他

欧洲人体微生物组-市场细分



按应用< /strong>
•治疗学
•诊断

按国家/地区


•美国
•加拿大
•墨西哥

提及的公司


• Enterome
• MicroBiome Therapeutics, LLC
• Rebiotix Inc.
•养乐多本社株式会社
• Osel Inc.
•韦丹塔生物科学公司
•元生物组学公司
•合成生物制剂公司
•杜邦
• BiomX 有限公司

Europe Human Microbiome Strategic Insights

Strategic insights for Europe Human Microbiome involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-human-microbiome-market-strategic-framework.webp
Get more information on this report

Europe Human Microbiome Report Scope

Report Attribute Details
Market size in 2017 US$ 72.34 Million
Market Size by 2025 US$ 346.67 Million
Global CAGR (2018 - 2025) 22.2%
Historical Data 2015-2016
Forecast period 2018-2025
Segments Covered By 产品
  • 益生菌
  • 食品
  • 益生元
  • 医疗食品
  • 诊断设备
  • 药物
  • 补充剂
By 疾病
  • 肥胖症
  • 糖尿病
  • 自身免疫性疾病
  • 癌症
  • 精神障碍
By 应用
  • 治疗学
  • 诊断学
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd.
  • Get more information on this report

    Europe Human Microbiome Regional Insights

    The regional scope of Europe Human Microbiome refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-human-microbiome-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Human Microbiome Market

    The List of Companies

    1. Enterome
    2. MicroBiome Therapeutics, LLC
    3. Rebiotix Inc.
    4. Yakult Honsha Co., Ltd.
    5. Osel Inc.
    6. Vedanta Biosciences, Inc.
    7. Metabiomics Corporate
    8. Synthetic Biologics, Inc.
    9. DuPont
    10. BiomX Ltd.
    Frequently Asked Questions
    How big is the Europe Human Microbiome Market?

    The Europe Human Microbiome Market is valued at US$ 72.34 Million in 2017, it is projected to reach US$ 346.67 Million by 2025.

    What is the CAGR for Europe Human Microbiome Market by (2018 - 2025)?

    As per our report Europe Human Microbiome Market, the market size is valued at US$ 72.34 Million in 2017, projecting it to reach US$ 346.67 Million by 2025. This translates to a CAGR of approximately 22.2% during the forecast period.

    What segments are covered in this report?

    The Europe Human Microbiome Market report typically cover these key segments-

  • 产品 (益生菌, 食品, 益生元, 医疗食品, 诊断设备, 药物, 补充剂)
  • 疾病 (肥胖症, 糖尿病, 自身免疫性疾病, 癌症, 精神障碍)
  • 应用 (治疗学, 诊断学)
  • What is the historic period, base year, and forecast period taken for Europe Human Microbiome Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Human Microbiome Market report:

  • Historic Period : 2015-2016
  • Base Year : 2017
  • Forecast Period : 2018-2025
  • Who are the major players in Europe Human Microbiome Market?

    The Europe Human Microbiome Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Enterome
  • MicroBiome Therapeutics, LLC
  • Rebiotix Inc.
  • Yakult Honsha Co., Ltd.
  • Osel Inc.
  • Vedanta Biosciences, Inc.
  • Metabiomics Corporate
  • Synthetic Biologics, Inc.
  • DuPont
  • BiomX Ltd.
  • Who should buy this report?

    The Europe Human Microbiome Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Human Microbiome Market value chain can benefit from the information contained in a comprehensive market report.